A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGF β3 Antibody, in Healthy Volunteers

ConclusionRO7303509 was well tolerated at single SC doses up to 1200  mg in HVs with favorable pharmacokinetic data that appeared to increase dose-proportionally. TGFβ3-specific inhibition may be suitable for development as a chronic antifibrotic therapy.Trial RegistrationISRCTN13175485.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research